Home > Boards > US OTC > Gaming and Casinos > Victory Square Technologies Inc. (VSQTF)

NetworkNewsAudio – PRVCF's Unique Delivery Platform Could be

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
NetworkNewsWire Member Profile
Member Level 
Followed By 37
Posts 4,157
Boards Moderated 3
Alias Born 10/18/16
160x600 placeholder
NetworkNewsWire Member Level  Friday, 02/23/18 03:56:01 PM
Re: None
Post # of 395 
Compensated Awareness Post - View Disclaimer
NetworkNewsAudio – PRVCF's Unique Delivery Platform Could be a Breakthrough in Cannabinoid Drug Delivery

Related Editorial
Modern science has substantiated both the anecdotal history and the efficacy of cannabidiol (“CBD”), a non-psychoactive compound found in the cannabis sativa plant. Research has revealed that CBD may significantly reduce inflammation and is now widely used to treat chronic pain, multiple sclerosis and fibromyalgia, epilepsy, and numerous other conditions. There is even evidence that CBD has potential to prevent symptoms of Alzheimer’s and appears to suppress the growth of cancer cells and promote the death of these cells (http://nnw.fm/S6cXu). While CBD may provide solutions to multiple unmet medical needs, current drug delivery techniques remain antiquated. There are inherent metabolic issues in consistent, effective delivery of cannabinoids, and these new pharmaceutical therapeutics require revolutionary techniques of administration. Establishing a new paradigm in cannabinoid drug delivery, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (PRVCF Profile) is engineering a unique Sol-gel nose-to-brain delivery platform to provide direct, controlled pharmacological drug release. Many large Canadian companies produce cutting-edge pharmaceutical cannabis compounds, yet rely on outdated delivery mechanisms and may find PreveCeutical’s platform superior to current dosing techniques. Some of these companies include Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF), Aphria, Inc. (TSX: APH) (OTCQB: APHQF) and Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F).

To hear the NetworkNewsAudio version, visit: http://nnw.fm/MAut8

To view the full editorial, visit http://nnw.fm/z62Bc

About PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com.

\
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist